1. Home
  2. TAC vs ERAS Comparison

TAC vs ERAS Comparison

Compare TAC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TransAlta Corporation

TAC

TransAlta Corporation

HOLD

Current Price

$12.48

Market Cap

4.2B

Sector

Utilities

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$18.31

Market Cap

4.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TAC
ERAS
Founded
1909
2018
Country
Canada
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
4.0B
IPO Year
2001
2021

Fundamental Metrics

Financial Performance
Metric
TAC
ERAS
Price
$12.48
$18.31
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
12
Target Price
$23.67
$14.25
AVG Volume (30 Days)
1.0M
4.1M
Earning Date
05-06-2026
05-08-2026
Dividend Yield
1.57%
N/A
EPS Growth
N/A
36.23
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$6.48
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.38
$1.33
52 Week High
$17.88
$24.28

Technical Indicators

Market Signals
Indicator
TAC
ERAS
Relative Strength Index (RSI) 40.32 53.35
Support Level $12.16 $17.36
Resistance Level $13.06 $19.96
Average True Range (ATR) 0.39 1.00
MACD -0.08 -0.19
Stochastic Oscillator 16.83 50.35

Price Performance

Historical Comparison
TAC
ERAS

About TAC TransAlta Corporation

TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse electrical power generation assets in Canada, the United States, and Western Australia. The company has reportable segments namely, Hydro, Wind & Solar, Gas, Energy Transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: